Spire Wealth Management’s Cytokinetics CYTK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-43
Closed -$1.51K 2420
2023
Q1
$1.51K Sell
43
-6
-12% -$245 ﹤0.01% 2316
2022
Q4
$2K Buy
+49
New +$2.11K ﹤0.01% 2028

Other funds holding CYTK

Spire Wealth Management's CYTK Position: Q2 2023 in Review

Spire Wealth Management sold out of Cytokinetics (CYTK) in Q2 2023, closing a stake of 43 shares — an estimated $1.51K sold.

Spire Wealth Management first reported a position in CYTK in Q4 2022 and held it in 2 quarters. The position peaked at $2K in Q4 2022. 253 funds tracked by Wall St. Rank hold CYTK as of Q2 2023.

  • Spire Wealth Management reported no remaining Cytokinetics position as of Q2 2023 after selling out during the quarter.
  • Spire Wealth Management sold 43 Cytokinetics shares in Q2 2023, an estimated $1.51K.
  • Spire Wealth Management first reported a position in Cytokinetics in Q4 2022 and held it in 2 quarters.
  • Spire Wealth Management's Cytokinetics position peaked at $2K in Q4 2022.
  • 253 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2023.

Based on Spire Wealth Management's 13F filing for Q2 2023, filed 9 Aug 2023.